Nuvectis Pharma (NASDAQ:NVCT) Issues Earnings Results

Nuvectis Pharma (NASDAQ:NVCT) released its quarterly earnings data on Tuesday. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.08), Zacks reports.

Nuvectis Pharma Price Performance

NVCT stock opened at $7.26 on Tuesday. Nuvectis Pharma has a 1 year low of $4.44 and a 1 year high of $12.10. The company has a 50 day simple moving average of $6.14 and a 200 day simple moving average of $6.40. The stock has a market cap of $140.24 million, a price-to-earnings ratio of -6.21 and a beta of 0.22.

Insider Buying and Selling

In other Nuvectis Pharma news, major shareholder Marlio Charles Mosseri bought 17,000 shares of the firm’s stock in a transaction dated Friday, December 13th. The stock was bought at an average cost of $4.70 per share, with a total value of $79,900.00. Following the completion of the transaction, the insider now directly owns 2,612,000 shares in the company, valued at approximately $12,276,400. The trade was a 0.66 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders purchased a total of 261,500 shares of company stock valued at $1,300,825 in the last three months. Insiders own 35.78% of the company’s stock.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.